Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc.ACXP · Entity 8195 | Director | April 20, 2026 | April 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acurx Pharmaceuticals, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2036-04-20 | Direct | 2,150 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 2,150 · Balance 2,150 F1: This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 22, 2026 16:20 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 2,150 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001104659-26-046842 · tm2612397-6_4seq1.xml · derivative · entry 1 Donohue James J. · CIK 0001869107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,150 Underlying: Common Stock · 2,150 shares Expires 2036-04-20 F1 · shares: This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 16:31 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 9,852 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001104659-25-002051 · tm252665-3_4seq1.xml · derivative · entry 2 Donohue James J. · CIK 0001869107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,852 Underlying: Common Stock · 9,852 shares Expires 2030-01-07 F2 · shares: Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 16:31 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 9,852 | $1.02 | $9,999.78 |
DisclosureSEC source: 0001104659-25-002051 · tm252665-3_4seq1.xml · nonDerivative · entry 1 Donohue James J. · CIK 0001869107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,352 F1 · shares: Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 16:11 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 12,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001104659-24-072808 · tm2417510-2_4seq1.xml · derivative · entry 1 Donohue James J. · CIK 0001869107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 17, 2025. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 17:46 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001104659-23-072372 · tm2319012-5_4seq1.xml · derivative · entry 1 Donohue James J. · CIK 0001869107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 15, 2024. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:12 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001104659-21-089408 · tm2121302d2_4seq1.xml · derivative · entry 1 Donohue James J. · CIK 0001869107 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. 1/36th of the shares granted shall become vested and exercisable as of each monthly anniversary from July 1, 2021, such that all shares subject to this stock option shall be fully vested and exercisable by July 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.